Is Foundayo available in the UK yet?
Not quite, but very soon. The MHRA approved Foundayo (orforglipron) on 10 August 2026, making the UK the first country in Europe where the once-daily GLP-1 tablet can be prescribed. Approval and availability are two different things, though: stock has to reach UK pharmacies and clinical services before the first prescriptions can be written, and that is expected over the coming weeks.
As with every GLP-1 weight-management medicine so far, the first route will be private prescription through regulated online clinics and pharmacy services. The United States, which approved orforglipron in April 2026, saw exactly this pattern: private and specialist services first, heavy early demand, and supply settling over the following months. If you want the full background on the approval, including what orforglipron is, the trial results and how it compares with the injections, start with our guide to Foundayo's UK approval.
Who will be eligible for Foundayo?
The UK licence follows the pattern set by the established GLP-1 treatments, covering weight management and type 2 diabetes:
Meeting the licence criteria is the starting point, not the finish line. A prescribing clinician also weighs your medical history, other conditions and current medicines. GLP-1 treatments are not suitable during pregnancy or breastfeeding, for example, and some medical histories rule them out. That individual assessment is exactly what the consultation is for.
How getting Foundayo will work, step by step
If you have read our guide on how to get Mounjaro in the UK, the process for Foundayo will look familiar: the assessment route is the same, only the medicine at the end of it is new.
One practical note for launch: because Foundayo is new and interest is high, early stock is likely to be limited and services may prioritise patients who have already completed their clinical assessment. Having your consultation done ahead of launch is the single most useful thing you can do if you want to be at the front of the queue when supply arrives.
How Foundayo compares with the options available now
Foundayo will not arrive into an empty field: UK patients already have well-established GLP-1 routes, and the right choice is as much practical as clinical.
Notice what Foundayo does and does not change. It removes the two most common practical objections, needles and fasting routines, and that alone will make clinical weight management feel accessible to people who have been sitting on the fence. What it does not do is beat the strongest injectables on raw trial numbers, which is why this is a genuine clinical conversation rather than an automatic upgrade: for some people the tablet's convenience will be worth more than a few percentage points of average difference; for others it will not.
Can you get Foundayo on the NHS?
Not yet. NICE, the body that decides what the NHS routinely funds in England, has its appraisal of orforglipron scheduled for 18 November 2026. Until that concludes, Foundayo will not be routinely available on the NHS, and private prescription will be the main route.
Even if NICE approves it, expect NHS access to be phased and narrower than the licence, as has happened with the injectable weight-management medicines, typically starting with the highest-need patients through specialist weight-management services. For most people who meet the licence criteria but not the tighter NHS criteria, private treatment is likely to remain the practical route for some time.
How much will Foundayo cost in the UK?
The manufacturer has not yet announced UK pricing, so treat any specific figure you see quoted today with caution. What we can say: each pack contains 30 tablets, one month of treatment at any strength, and private GLP-1 weight-management programmes in the UK currently tend to sit roughly between £120 and £250 a month depending on the medicine and dose.
There is a reasonable case that Foundayo could land competitively within that range over time. Orforglipron is a small-molecule tablet, which is simpler to manufacture and distribute at scale than an injectable peptide: no pens, no needles, no cold chain. That said, new medicines rarely launch cheap while demand outstrips supply, so realistic expectations for launch pricing are sensible. For a deeper look at the pricing question, including how the injectable programmes are priced today, see our dedicated guide to how much Foundayo will cost in the UK.
Staying safe: unlicensed sellers and too-good-to-be-true prices
Every high-profile weight-management launch is followed by a wave of unlicensed sellers, and Foundayo will be no different. Genuine Foundayo will only be available with a prescription, from a clinician-led service, dispensed by a pharmacy you can verify on the GPhC register. Anything offered without a consultation, on social media, from overseas websites, or at a price dramatically below the market, should be treated as counterfeit until proven otherwise.
This matters more than usual for a brand-new medicine, because early scarcity is exactly the gap counterfeiters exploit. Our guide to unlicensed weight-loss products sold online covers the warning signs in detail.
What you can do today
If Foundayo interests you, the sensible sequence is: consultation first, medicine decision second. A UK-registered clinician can assess whether a GLP-1 treatment is appropriate for you at all, and if it is, you can decide together whether to start now with an established option such as Wegovy or Mounjaro and review once Foundayo arrives, or wait for the tablet if the injectable route is what has been holding you back. Waiting is a perfectly reasonable choice; waiting without getting assessed is simply a slower start.
Either way, the assessment you complete now stays valid at launch, and switching between GLP-1 medicines, where appropriate, is a routine clinical decision your prescriber can manage. You can browse everything we cover on this topic in our weight-management guides.